LETTER TO THE EDITOR
Reply to the letter “Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B”
Valerie Ohlendorf,
Valerie Ohlendorf
Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany
Search for more papers by this author Benjamin Maasoumy,
Corresponding Author
Benjamin Maasoumy
Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany
German Center for Infection Research (DZIF), Partner-Site Hannover-Braunschweig, Hannover, Germany
Correspondence
Benjamin Maasoumy, Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany.
Email: [email protected]
Search for more papers by this author
Valerie Ohlendorf,
Valerie Ohlendorf
Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany
Search for more papers by this author Benjamin Maasoumy,
Corresponding Author
Benjamin Maasoumy
Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany
German Center for Infection Research (DZIF), Partner-Site Hannover-Braunschweig, Hannover, Germany
Correspondence
Benjamin Maasoumy, Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany.
Email: [email protected]
Search for more papers by this author
First published: 24 February 2023
No abstract is available for this article.
REFERENCES
- 1Huang C-B, Su T-H, Kao J-H. Letter to the editor: anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B. Liver Int. Published online February 2, 2023. doi: 10.1111/liv.15536
- 2Ohlendorf V, Wübbolding M, Gineste P, et al. Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients. Liver Int. 2022; 42(12): 2674-2682. doi:10.1111/liv.15433
- 3Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016; 63(5): 1481-1492. doi:10.1002/hep.28438
- 4Hall SAL, Vogrin S, Wawryk O, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut. 2022; 71(8): 1629-1641. doi:10.1136/gutjnl-2020-323979
